![](https://www.ua-magazine.com/wp-content/uploads/2020/11/sputnik-V-e1606388838196.jpg)
Sputnik V vaccine is 91,4% effective
The second analysis of Phase III trials—obtained 28 days after administering the first dose and 7 days after the second —shows that the vaccine developed in Russia has a 91,4% efficacy.
![](https://www.ua-magazine.com/wp-content/uploads/2020/11/128px-Coat_of_Arms-Seal_of_Oxford_University.png)
Oxford & AstraZeneca Vaccine candidate shows 70% protection
The candidate Oxford Covid-19 vaccine reduced transmission by 70% in trial participants who received a two-dose regimen. But the dosing scheme of this vaccine is yet to be clarified.
![](https://www.ua-magazine.com/wp-content/uploads/2020/11/Food_and_Drug_Administration_logo.svg_-e1606388788428.png)
Pfizer files emergency use authorization to FDA
After having announced a 95% efficacy of their candidate Covid-19 vaccine, Pfizer and BioNTech requested an Emergency Use Authorization to FDA (Food and Drug Administration). The US agency will analyze the request on December 10.
![](https://www.ua-magazine.com/wp-content/uploads/2020/11/logo-pfizer-e1606388765868.jpeg)
Pfizer and BioNTech announce complete results from Phase III trials
The mRNA-based candidate vaccine was shown to prevent 95% of cases of Covid-19.
![](https://www.ua-magazine.com/wp-content/uploads/2020/11/moderna-e1606388814812.png)
Moderna’s candidate vaccine is 94,5% effective
Over 30,000 participants were enrolled in the trials in the U.S. The biotechnological company plans to submit an authorization request in the following weeks.
Images Credit:
Mos.ru, CC BY 4.0, via Wikimedia Commons,
Rs-nourse, CC BY-SA 4.0, via Wikimedia Commons,
https://en.wikipedia.org/wiki/File:Moderna_Therapeutics_company_logo.png with UploadWizard, CC BY-SA 3.0
Press Releases:
AstraZeneca: https://www.ox.ac.uk/news/2020-11-23-oxford-university-breakthrough-global-covid-19-vaccine
Pfizer: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-conclude-phase-3-study-covid-19-vaccine
Moderna: https://investors.modernatx.com/news-releases/news-release-details/modernas-covid-19-vaccine-candidate-meets-its-primary-efficacy